A pan-cancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB)

Authors:

Wafik S. El-Deiry, Taylor Arnoff, Ilyas Sahin, Hossein Borghaei, Vivek Subbiah, Hina Khan, Benedito A. Carneiro, Howard Safran, Stephanie L. Graff, Don S. Dizon, Elisabeth I. Heath, Eric T. Wong, Abbas Abbas, Christopher G. Azzoli, Michael J. Demeure, Jim Abraham, Razelle Kurzrock, Joanne Xiu, Emil Lou, Stephen V. Liu

Key Finding:

MDM2 and MDM4 amplification are negative prognostic factors in TP53-wildtype breast cancer, while MDM4 amplification is associated with reduced survival in immune checkpoint blockade-treated non-small cell lung cancer. 

Download Publication